secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2025-09-15T23:59:59+00:00
Accession:  0001645113-25-000037
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Japan MHLW approves Novocure's Optune Lua for advanced NSCLC
------------------------------------------------------------

- Japan MHLW approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors in advanced/recurrent NSCLC after platinum-based chemo.
- Approval based on Phase 3 LUNAR trial: median OS 13.2 vs 9.9 months (3.3-month improvement, p=0.04).
- In PD-1/PD-L1 subgroup, median OS 19.0 vs 10.8 months (8.2-month improvement, p=0.02).
- Optune Lua is a wearable TTFields device; device-related AEs were mostly grade 1-2 skin reactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000037/0001645113-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000037/nvcr-20250915.htm
  HTML page:      https://secwatch.observer/filing/0001645113-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer